

- Supporting Information -

Assessing Inorganic Nanoparticle Toxicity through Omics Approaches

Yanchen Li,¹ Christopher Vulpe,² Twan Lammers,¹ and Roger M. Pallares^{1,*}

¹ Institute for Experimental Molecular Imaging, RWTH Aachen University Hospital, Aachen 52074, Germany

² Center for Environmental and Human Toxicology, Department of Physiological Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL, 32611, USA

* Corresponding author: rmoltopallar@ukaachen.de

Table of Contents

Figure S1. Overview of omics techniques for assessing nanoparticle toxicityS2

Figure S2. Summary of omics studies that characterize the toxicity of nanoparticles.S3




Figure S1. Overview of the omics techniques used for assessing nanoparticle toxicity discussed in the review.

Table S1. Summary of omics studies that characterize the toxicity of nanoparticles

Nanoparticle properties			Shell properties		Toxicity testing			Ref.
Type	Size (nm)	Shape	Shell material	Charge	Testing type	Model	Omics	
AgNPs	20	Spherical	n/a	n/a	In vitro	Human dermal fibroblasts-fetal (HDF-f) cells	Transcriptomics	¹⁰⁰
AgNPs	20	Spherical	n/a	n/a	In vitro	Human dermal fibroblasts-fetal (HDF-f) cells	Transcriptomics	¹⁰¹
AgNPs	10, 30, and 60	Spherical	Citrate, polyethylene glycol (PEG), bovine serum albumin (BSA)	Citrate-coated NPs: Negative (-29 ~ 43 mV) PEG-/BSA- coated NPs: Negative (-12 ~ 18 mV)	In vitro	Human skin keratinocytes (HaCaT) cells	Metabolomics	¹⁰²
AgNPs	15.9 ± 7.6	Spherical	Citrate	Negative (-21.6 ± 1.3 mV)	In vitro	Human lung epithelial (A549) cells	Transcriptomics	¹⁰⁵
AgNPs	5 and 100	Spherical	PVP	n/a	In vitro	Human endothelial (EA.hy926) cells and bronchial epithelial (BEAS-2B) cells	Transcriptomics	¹⁰⁶
AgNPs	7-10	n/a	Polyethylenimine	n/a	In vitro	Human hepatoma (HepG2) cells	Transcriptomics	¹⁰⁹
AgNPs	16.1 ± 5.3	Spherical	PVP	Negative (-19 mV)	In vitro	Carp gill mitochondria	Proteomics	¹¹⁰
AgNPs	20-50	Spherical	GSH	Negative (-8~10 mV)	In vitro	Human hepatoma (HepG2) cells	Transcriptomics	¹¹¹
AgNPs	91.7 ± 1.6	Spherical	n/a	Negative (- 6.3 ± 0.4 mV)	In vitro	Human hepatoma (HepG2) cells	Lipidomics	⁷⁷
AgNPs	30	Spherical	Citrate	n/a	In vitro	Human colon adenocarcinoma (Caco-2) cells	Proteomics	¹¹²
AgNPs	25	n/a	n/a	n/a	In vivo	Colon tissue of male C57BL/6J mice	Transcriptomics	¹¹⁵
AgNPs	10 and 40	Spherical	Citrate	n/a	In vivo	Zebrafish embryos	Transcriptomics	¹¹⁶
AgNP	25.5	n/a	n/a	n/a	In vivo	Zebrafish embryos	Metabolomics	¹¹⁷
AuNPs	21.8 ± 4.8	Spherical	Citrate	n/a	In vitro	Human dermal fibroblast (HDF-f) cells	Transcriptomics	¹²⁷
AuNPs	20	Spherical	n/a	n/a	In vitro	Human lung epithelial (A549) cells	Metabolomics	¹²⁸
PdNPs	10	Spherical	Hesperidin	Negative (-15.4 ± 1.3mV)	In vitro	Human ovarian cancer (SKOV3) cells	Transcriptomics	¹⁴¹
PdNPs	141.3 ± 5.5	Spherical	n/a	Positive (49.2 ± 1.9mV)	In vivo	Earthworms	Transcriptomics	¹⁴²
PdNPs	10 ± 6	n/a	n/a	Negative (-25.9 ± 5.6 mV)	In vitro	rat embryo fibroblasts (Rat-1) and human lung epithelial (A549) cells	Proteomics	¹⁴³

TiO ₂ NPs	7, 20, and 200	n/a	n/a	n/a	In vitro	Human epidermal keratinocyte (HaCaT) cells	Transcriptomics	169
TiO ₂ NPs	20.6	Spherical	n/a	n/a	In vivo	Bronchoalveolar lavage (BAL) and lung tissue of female C57BL/6 mice	Transcriptomics and proteomics	171
TiO ₂ NPs	6	n/a	Hydroxypropyl methylcellulose (HPMC)	Positive (9.28 mV)	In vitro	Bronchoalveolar lavage (BAL) and lung tissue of female CD-1 mice	Transcriptomics	172
TiO ₂ NPs	25	Spherical	n/a	Negative (-21.0 ± 0.7 mV)	In vitro	Human hepatoma (HepG2) cells	Transcriptomics	177
TiO ₂ NPs	25	Spherical	n/a	Negative (-10.8 mV)	In vivo	Lung tissue of female NIH mice	Transcriptomics and epigenomics	173
TiO ₂ NPs	n/a	n/a	n/a	n/a	In vitro	Lung fibroblast (MRC5) cells	Epigenomics	174
TiO ₂ NPs	< 25	Spherical	n/a	n/a	In vitro	Human epidermal keratinocytes (HaCaT) cells	Transcriptomics and proteomics	170
CeO ₂ NPs	4.0 ± 1.1	n/a	Tetra-methyl ammonium hydroxide (TMAOH)	Negative (-45 mV)	In vitro	Human lung epithelial (A549) cells and bronchial (BEAS-2B) epithelial cells	Transcriptomics	205
CeO ₂ NPs	8	Spherical	n/a	n/a	In vivo	Lung tissue of Sprague-Dawley (SD) rats	Lipidomics and transcriptomics	8
ZnONPs	100 and 300	n/a	Triethoxycaprylylsilane	n/a	In vivo	Bronchoalveolar lavage (BAL) fluid cellularity of female C57BL/6J BomTac mice	Transcriptomics	184
ZnONPs	20–50	Spherical	n/a	Positive (20.0 ± 6.5 mV)	In vitro and in vivo	Human hepatoma (HepG2) cells	Transcriptomics	185
ZnONPs	158	Rectangular, rod, spherical, and irregular shapes	n/a	Negative (-19 ± 1 mV)	In vitro	Alveolar macrophages (NR8383)	Transcriptomics and proteomics	188
ZnONPs	355.6 ± 68.2	Spherical	n/a	Negative (-17.9 ± 0.2 mV)	In vivo	Female and male zebrafish (Danio rerio)	Transcriptomics and metabolomics	186
NiONPs	750	n/a	n/a	n/a	In vitro	Human bronchial epithelial (BEAS-2B) cells	Transcriptomics	208
SPIONs	10	Irregular	Citric acid	Negative (-40 mV)	In vitro	Human submandibular gland (HSG) cells	Transcriptomics and epigenomics	195
SPIONs	20	n/a	n/a	Positive (27.4 ± 1.1 mV)	In vitro	Mouse macrophage (RAW 264.7) cells	Proteomics and lipidomics	197
V ₂ O ₅ NPs	36 ± 2	Irregular	n/a	n/a	In vitro	Human bronchial epithelial (BEAS-2B) cells	Metabolomics	206
CdTe quantum dots	55.6	n/a	n/a	n/a	In vitro	Human monocyte (THP-1) cells	Proteomics	218
SiNPs	65.0 ± 7.4	Spherical	n/a	Negative (-20.5 ± 1.5 mV)	In vitro	Spermatocyte (GC-2spd) cells	Transcriptomics	223
SiNPs	58	Spherical	n/a	Negative (-30 mV)	In vitro	Human hepatic (L-02) cells	Metabolomics and proteomics	224

WBNPs	149	n/a	n/a	n/a	In vitro	Human lung alveolar epithelial (HPAEpiC) cells	Transcriptomics	¹⁴⁷
PtNPs	5-45	Spherical	Lycopene	n/a	In vitro	Human acute monocytic leukemia (THP-1) cells	Transcriptomics	¹⁵⁵
Gd ₂ O ₃ NPs	3-4	n/a	n/a	n/a	In vitro and in vivo	4T1 breast cancer cells and female Bal/bc mice	Genomics, transcriptomics and metabolomics	²⁰⁹
MoO ₂ NPs	64 ± 18	Spherical	PVP	Negative (<-30 mV)	In vitro	Rat type II alveolar epithelial cells	Transcriptomics, metabolomics and proteomics	²¹¹
Mn ₃ O ₄ NPs	100	n/a	n/a	n/a	In vitro	Lung epithelial (CCL-149) cells	Transcriptomics	²¹⁰